Cereno Scientific

“With the company's upcoming data quality control of CardioMEMS in the Phase II study with CS1 in PAH during Q4 2023, which also gives us the opportunity to report early efficacy data, it is a strong statement that everyone in the company's management and board acquired a large number of warrants. I am also very pleased that we are now connecting some of the industry's most experienced and meritorious researchers even closer," said Joakim Söderström, chairperson of the board of Cereno Scientific. 

The persons who have acquired warrants of series 2023/2026:1 within the framework of the incentive program are as follows:

• Sten R. Sörensen, CEO, 5 000 000 warrants
• Björn Dahlöf, CMO, 2 500 000 warrants
• Eva Jagenheim, CFO, 1 000 000 warrants
• Nicholas Oakes, Head of Preclinical Development, 250 000 warrants
• Fredrik Frick, Head of Clinical Operations, 300 000 warrants

• Dr. Raymond L Benza, Scientific Advisor, 1 000 000 warrants
• Dr. Michael Holinstat, Director of Translational Research, 1 000 000 warrants
• Dr. Gunnar Olsson, Scientific Advisor, 500 000 warrants

Board members who have signed warrants of series 2023/2026:2 within the framework of the incentive program are as follows:

• Joakim Söderström, Chairperson, 3 000 000 warrants
• Jonas Faijerson Säljö, member and Chief Intellectual Property Officer, 1 000 000 warrants
• Sverker Jern, member and co-founder, 1 000 000 warrants
• Lena Mårtensson, member, 500 000 warrants
• Anders Svensson, member, 1 000 000 warrants

For further information, please contact:

Eva Jagenheim, CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.